Tag: INSIGHT-004 Phase I trial
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
Australian Manufacturing Week 2026 enters final run-up to Brisbane debut
Australia’s manufacturing sector continues to play a critical role in the national economy, underpinned by ongoing investment in advanced technologies, automation, and high-value production.
